Zevra Therapeutics, Inc. (ZVRA)

Market Cap	611.19M +53.7%
Revenue (ttm)	106.47M +350.9%
Net Income	77.59M
EPS	1.35
Shares Out	58.71M
PE Ratio	7.74
Forward PE	22.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,998,595
Open	10.76
Previous Close	11.06
Day's Range	9.54 - 10.85
52-Week Range	6.19 - 13.16
Beta	0.94
Analysts	Strong Buy
Price Target	21.71 (+108.55%)
Earnings Date	Mar 9, 2026

About ZVRA

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical tria...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 16, 2015
• Employees: 59
• Stock Exchange: NASDAQ
• Ticker Symbol: ZVRA
• Website: https://zevra.com

Analyst Summary

According to 7 analysts, the average rating for ZVRA stock is "Strong Buy." The 12-month stock price target is $21.71, which is an increase of 108.55% from the latest price.

Price Target

$21.71

(108.55% upside)

Analyst Consensus: Strong Buy